Pharmaceuticals company Bajaj Healthcare announced Q2FY26 results Q2FY26 Financial Highlights: Revenue stood at Rs 1479 million for Q2FY26 compared to Rs 1330 million for Q2FY25 EBITDA stood at Rs 286 million for Q2FY26 compared to Rs 271 million for Q2FY25 PAT for the period stood at Rs 111 million for Q2FY26 compared to Rs 94 million for Q2FY25 Q2FY26 Business Highlights: Received SEC-CDSCO recommendation to initiate Phase III clinical trials for Suvorexant Tablets, becoming the first company in India to secure this nod for the insomnia molecule. Secured DCGI approval to conduct phase III clinical trials for Cenobamate Tablets, a novel anti-epileptic molecule; the clinical trials are currently underway. Filed two new CEPs during the quarter, taking cumulative filings to ten (seven approved, three under review); two additional CEPs currently in progress, further strengthening our position in regulated EU and UK markets. During this quarter, we have filed few DMFs. Overall, till date we have filed 60 DMFs in various countries. We will continue to strengthen our regulatory filings. Anil Jain – Managing Director said, “Our Q2FY26 performance underscores the resilience of our operations and the strength of our strategic execution, despite ongoing tariff tensions and global uncertainty. Revenue from operations grew 11% year-on-year. Sequentially, gross margin expanded by 462 basis points to 50.8%, while EBITDA margin improved by 217 basis points to 19.1%, resulting in profit from continuing operations growing by a strong 49% year-on-year and reaffirming our focus on sustainable earnings growth. This improvement in margins and profitability was driven by strong growth in exports (up 67% year-on-year) and formulations during the quarter. While pricing pressure persists in the domestic API segment, we continue to pursue opportunities in high-margin products to support long-term margin stability. On the regulatory front, we continue to strengthen our global compliance framework and advance product registrations across key geographies. Our focus remains on expanding our presence in regulated markets and aligning our pipeline with high-value therapeutic areas that offer long-term growth potential. With a strong foundation, enhanced regulatory preparedness, and continued investment in R&D;, we are well-positioned to sustain growth momentum and drive expansion across our API and formulations businesses. We have also strengthened our key management people with industry leaders across key divisions, enabling us to achieve sustainable and scalable growth. We remain committed to creating long-term value for the healthcare ecosystem and our stakeholders.” Result PDF